The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases for prescription drugs. The state this year began requiring drug makers to report WAC increases for drugs when they exceed 16% over two years, including the reasons for the increases if publicly available. The three-year median increase for drug makers submitting data in first-quarter 2019 was 25.8%. Generic drugs experienced the largest median increase at 37.6% overall and 156.4% for those under $100. Brand name drugs with a wholesale cost greater than $10,000 rose a median 30.4%. More than two-thirds of those submitting data did not provide reasons for the price increases.
 

Related News Articles

Headline
About 84% of hospitals had posted a machine-readable file containing rate information by the end of first-quarter 2023, up from 65% the previous quarter,…
Headline
The CMS Innovation Center will test three new models to see whether they lower high drug costs, the Centers for Medicare & Medicaid Services announced…
Headline
The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and…
Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…
Headline
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug…
Blog
A recent report from UnitedHealth comparing specialty drug spending in hospitals and independent physician offices fails to account for critical differences…